Date

Tuesday, 14 February 2017

Location

European Medicines Agency, Amsterdam, the Netherlands

The Committee for Orphan Medicinal Products (COMP) is the committee that is responsible for reviewing applications for 'orphan medicinal product designation' for medicines intended for the diagnosis, prevention or treatment of rare diseases.

Documents

COMP meeting report on the review of applications for orphan designation: February 2017

Agenda - COMP agenda of the 14-16 February 2017 meeting

Minutes of the COMP meeting 14-16 February 2017

How useful do you find this page?